idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Researchers at the Department of Biotechnology of Technische Universität Braunschweig started a research project to develop novel antibody based therapy for coronavirus infections. To increase the chances of success, the international consortium pursues several parallel approaches of antibody-based therapies against the lung disease COVID-19 caused by the SARS-CoV2 virus. The research team of the Department of Biotechnology at TU Braunschweig will be responsible for the development of human antibodies, working in close cooperation with partners in Sweden, Belgium, Italy and Switzerland.
The consortium “ATAC” (Antibody Therapy Against Coronavirus) will be financed by the European Union with about 3 Million euro. In total, the European Commission has allocated 47 Million euro to 136 laboratories in 17 teams for the development of vaccines, diagnostics and therapies for COVID-19.
Antibodies for therapy have been in use for 125 years, because in contrast to conventional vaccines, they can be also used for the treatment of patients that are already ill. Emil von Behring was the first to use this therapeutic approach against diphtheria, which yielded him the Nobel Prize for medicine in 1901. From that date until today antisera from horses are still used for this type of therapy in most cases. In contrast, at TU Braunschweig, human antibodies will be generated with a technology called antibody phage display. This approach allows to generate human antibodies entirely in the test tube. Because this method also provides the molecular blueprint of these antibodies right away, they can be produced in cell culture in unlimited amounts and very high quality. Professor Stefan Dübel, head of the department of Biotechnology, an inventor of this technology, Professor Michael Hust, the principle investigator of this project, and their team have many years of experience in the development of neutralizing antibodies against viruses like Marburg virus, Ebola and HIV.
The development of therapeutic antibodies against COVID-19 is expected to take several months to a year, in particular because of necessary efficacy and safety tests.
More information:
ATAC Consortium members are the Karolinska Institutet (Sweden, Qiang Pan-Hammarström and Lennart Hammarström, coordinators), the Institute for Research in Biomedicine (Switzerland, Luca Varani and Davide Robbiani), the Joint Research Centre- European Commission (Belgium, Luigi Calzolai), Policlinico San Matteo (Italy, Fausto Baldanti) and Technische Universität of Braunschweig (Germany, Michael Hust). The partners’ outstanding expertise is attested by high impact publications on antibody treatment for emerging infectious diseases.
Prof. Dr. Michael Hust
Technische Universität Braunschweig
Institute of Biochemistry, Biotechnology and Bioinformatics
Department of Biotechnology
Spielmannstraße 7
38106 Braunschweig
Germany
Phone: +49 531 391-5760
E-Mail: m.hust@tu-braunschweig.de
www.bbt.tu-bs.de/Biotech
https://magazin.tu-braunschweig.de/en/pi-post/antiviral-antibodies/
An example of an antibody (symbolic picture).
Picture credits: Stefan Dübel/TU Braunschweig
None
Criteria of this press release:
Business and commerce, Journalists, Scientists and scholars
Biology, Medicine
transregional, national
Research projects
English
An example of an antibody (symbolic picture).
Picture credits: Stefan Dübel/TU Braunschweig
None
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
